Published in Biotech Business Week, January 29th, 2007
Celgene is purchasing the assets for approximately a total of CHF 55.5 million (US$44.51 million) in cash, with an initial payment of CHF 15 million (US$12.03 million). The manufacturing facility has the capability to produce multiple drug substances and initially will be used to produce Revlimid to supply global markets.
"This asset acquisition and collaboration further extends our global manufacturing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.